Are Concord Biotech latest results good or bad?

Concord Biotech has reported its financial results for the quarter ending March 2025, showcasing notable growth across several key metrics. The company achieved net sales of Rs 429.88 crore, which reflects a significant increase compared to the average of the previous four quarters. This figure represents the highest net sales recorded in the last five quarters. Profit Before Tax (PBT) less Other Income rose to Rs 174.16 crore, indicating substantial growth over the prior average. Similarly, Profit After Tax (PAT) climbed to Rs 140.39 crore, demonstrating a strong performance relative to earlier periods.
The operating profit also reached its peak in five quarters at Rs 190.42 crore, with an operating profit margin of 44.30%, suggesting improved operational efficiency. Earnings per share (EPS) hit a five-quarter high at Rs 13.42, reflecting enhanced profitability.

However, in the subsequent quarter ending June 2025, the company reported a decline in key financial metrics. Net sales showed a significant drop compared to the previous quarter, as did standalone net profit, which also experienced a notable decrease. The operating profit margin, while still positive, reflected a contraction from the previous quarter's performance.

Overall, the data indicates that while Concord Biotech experienced strong growth in the March 2025 quarter, the following quarter saw a decline in performance metrics. Additionally, the company saw an adjustment in its evaluation during this period.